Spruce Biosciences (OTC:SPRBD) Trading Up 40.9% – Should You Buy?

Spruce Biosciences, Inc. (OTC:SPRBD) shares rose 40.9% on Thursday . The stock traded as high as $12.75 and last traded at $12.40. Approximately 75,838 shares changed hands during trading, an increase of 675% from the average daily volume of 9,786 shares. The stock had previously closed at $8.80.

Spruce Biosciences Trading Up 40.9%

The stock has a market cap of $6.97 million, a PE ratio of -0.14 and a beta of 2.43. The firm’s 50-day moving average price is $12.40.

Spruce Biosciences, Inc is a clinical-stage specialty biopharmaceutical company focused on developing targeted therapies for rare endocrine diseases. The company’s research strategy centers on modulating the hormonal axis to address underlying disease mechanisms rather than treating symptoms alone. By concentrating on orphan indications with high unmet medical need, Spruce aims to deliver novel treatment options for patients who have limited alternatives under current standard-of-care regimens.

Spruce’s lead product candidate is tildacerfont, an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist in development for adults with classic congenital adrenal hyperplasia (CAH).